File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes
  • Basic View
  • Metadata View
  • XML View
TitleDistinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes
 
AuthorsXiao, Y1 2
Xu, A2 2 2
Law, LSC2
Chen, C2
Li, H1
Li, X1
Yang, L1
Liu, S1
Zhou, Z1
Lam, KSL2 2 2
 
Issue Date2012
 
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
 
CitationJournal of Clinical Endocrinology and Metabolism, 2012, v. 97 n. 1, p. E54-E58 [How to Cite?]
DOI: http://dx.doi.org/10.1210/jc.2011-1930
 
AbstractAims: Fibroblast growth factor (FGF) 21 is an endocrine factor with multiple beneficial effects on glucose and lipid metabolism in animals. This study aimed to investigate the association of serum FGF21 levels with type 1 diabetes, latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Methods: Serum FGF21 levels were determined by ELISA in patients with type 1 diabetes (n = 76), LADA (n = 68), type 2 diabetes (n = 77), and their age- and sex-matched controls. The association of serum FGF21 with markers of autoimmunity was studied. Results: In type 1 diabetic patients, serum FGF21 levels were significantly lower than controls [108.3 (61.5-180.1) vs. 196.0 (103.7-330.9) pg/ml, P < 0.001]. In LADA patients, serum FGF21 levels were significantly lower than controls after adjustment for body mass index [210.9 (121.4-441.6) vs. 268.3 (159.5-443.6) pg/ml, P = 0.003]. By contrast, serum FGF21 levels in type 2 diabetic patients were significantly higher than controls [381.2 (244.7-531.3) vs. 301.4 (173.9-444.2) pg/ml, P = 0.006]. FGF21 levels increased progressively from type 1 diabetes, LADA, to type 2 diabetes (P < 0.001 for global trend). Furthermore, FGF21 levels correlated inversely with titers of glutamic acid decarboxylase and insulinoma-associated protein 2 autoantibodies in type 1 diabetic and LADA patients. Conclusions: Serum FGF21 level is increased in type 2 diabetes but decreased in type 1 diabetes and LADA. In autoimmune diabetes, the reduction in circulating FGF21 is closely associated with markers of pancreatic β-cell autoimmunity. Copyright © 2012 by The Endocrine Society.
 
ISSN0021-972X
2012 Impact Factor: 6.43
2012 SCImago Journal Rankings: 2.555
 
DOIhttp://dx.doi.org/10.1210/jc.2011-1930
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorXiao, Y
 
dc.contributor.authorXu, A
 
dc.contributor.authorLaw, LSC
 
dc.contributor.authorChen, C
 
dc.contributor.authorLi, H
 
dc.contributor.authorLi, X
 
dc.contributor.authorYang, L
 
dc.contributor.authorLiu, S
 
dc.contributor.authorZhou, Z
 
dc.contributor.authorLam, KSL
 
dc.date.accessioned2012-09-05T05:32:39Z
 
dc.date.available2012-09-05T05:32:39Z
 
dc.date.issued2012
 
dc.description.abstractAims: Fibroblast growth factor (FGF) 21 is an endocrine factor with multiple beneficial effects on glucose and lipid metabolism in animals. This study aimed to investigate the association of serum FGF21 levels with type 1 diabetes, latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Methods: Serum FGF21 levels were determined by ELISA in patients with type 1 diabetes (n = 76), LADA (n = 68), type 2 diabetes (n = 77), and their age- and sex-matched controls. The association of serum FGF21 with markers of autoimmunity was studied. Results: In type 1 diabetic patients, serum FGF21 levels were significantly lower than controls [108.3 (61.5-180.1) vs. 196.0 (103.7-330.9) pg/ml, P < 0.001]. In LADA patients, serum FGF21 levels were significantly lower than controls after adjustment for body mass index [210.9 (121.4-441.6) vs. 268.3 (159.5-443.6) pg/ml, P = 0.003]. By contrast, serum FGF21 levels in type 2 diabetic patients were significantly higher than controls [381.2 (244.7-531.3) vs. 301.4 (173.9-444.2) pg/ml, P = 0.006]. FGF21 levels increased progressively from type 1 diabetes, LADA, to type 2 diabetes (P < 0.001 for global trend). Furthermore, FGF21 levels correlated inversely with titers of glutamic acid decarboxylase and insulinoma-associated protein 2 autoantibodies in type 1 diabetic and LADA patients. Conclusions: Serum FGF21 level is increased in type 2 diabetes but decreased in type 1 diabetes and LADA. In autoimmune diabetes, the reduction in circulating FGF21 is closely associated with markers of pancreatic β-cell autoimmunity. Copyright © 2012 by The Endocrine Society.
 
dc.description.natureLink_to_OA_fulltext
 
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2012, v. 97 n. 1, p. E54-E58 [How to Cite?]
DOI: http://dx.doi.org/10.1210/jc.2011-1930
 
dc.identifier.doihttp://dx.doi.org/10.1210/jc.2011-1930
 
dc.identifier.epageE58
 
dc.identifier.hkuros204675
 
dc.identifier.issn0021-972X
2012 Impact Factor: 6.43
2012 SCImago Journal Rankings: 2.555
 
dc.identifier.issue1
 
dc.identifier.pmid22013098
 
dc.identifier.scopuseid_2-s2.0-84862928486
 
dc.identifier.spageE54
 
dc.identifier.urihttp://hdl.handle.net/10722/163504
 
dc.identifier.volume97
 
dc.languageeng
 
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
 
dc.publisher.placeUnited States
 
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolism
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdolescent
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAutoimmunity - Physiology
 
dc.subject.meshBlood Glucose - Analysis
 
dc.subject.meshCase-Control Studies
 
dc.subject.meshChild
 
dc.subject.meshDiabetes Mellitus - Blood - Classification
 
dc.subject.meshDiabetes Mellitus, Type 1 - Blood
 
dc.subject.meshDiabetes Mellitus, Type 2 - Blood
 
dc.subject.meshFemale
 
dc.subject.meshFibroblast Growth Factors - Analysis - Blood
 
dc.subject.meshHumans
 
dc.subject.meshInsulin-Secreting Cells - Immunology
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.titleDistinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Xiao, Y</contributor.author>
<contributor.author>Xu, A</contributor.author>
<contributor.author>Law, LSC</contributor.author>
<contributor.author>Chen, C</contributor.author>
<contributor.author>Li, H</contributor.author>
<contributor.author>Li, X</contributor.author>
<contributor.author>Yang, L</contributor.author>
<contributor.author>Liu, S</contributor.author>
<contributor.author>Zhou, Z</contributor.author>
<contributor.author>Lam, KSL</contributor.author>
<date.accessioned>2012-09-05T05:32:39Z</date.accessioned>
<date.available>2012-09-05T05:32:39Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Journal of Clinical Endocrinology and Metabolism, 2012, v. 97 n. 1, p. E54-E58</identifier.citation>
<identifier.issn>0021-972X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/163504</identifier.uri>
<description.abstract>Aims: Fibroblast growth factor (FGF) 21 is an endocrine factor with multiple beneficial effects on glucose and lipid metabolism in animals. This study aimed to investigate the association of serum FGF21 levels with type 1 diabetes, latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Methods: Serum FGF21 levels were determined by ELISA in patients with type 1 diabetes (n = 76), LADA (n = 68), type 2 diabetes (n = 77), and their age- and sex-matched controls. The association of serum FGF21 with markers of autoimmunity was studied. Results: In type 1 diabetic patients, serum FGF21 levels were significantly lower than controls [108.3 (61.5-180.1) vs. 196.0 (103.7-330.9) pg/ml, P &lt; 0.001]. In LADA patients, serum FGF21 levels were significantly lower than controls after adjustment for body mass index [210.9 (121.4-441.6) vs. 268.3 (159.5-443.6) pg/ml, P = 0.003]. By contrast, serum FGF21 levels in type 2 diabetic patients were significantly higher than controls [381.2 (244.7-531.3) vs. 301.4 (173.9-444.2) pg/ml, P = 0.006]. FGF21 levels increased progressively from type 1 diabetes, LADA, to type 2 diabetes (P &lt; 0.001 for global trend). Furthermore, FGF21 levels correlated inversely with titers of glutamic acid decarboxylase and insulinoma-associated protein 2 autoantibodies in type 1 diabetic and LADA patients. Conclusions: Serum FGF21 level is increased in type 2 diabetes but decreased in type 1 diabetes and LADA. In autoimmune diabetes, the reduction in circulating FGF21 is closely associated with markers of pancreatic &#946;-cell autoimmunity. Copyright &#169; 2012 by The Endocrine Society.</description.abstract>
<language>eng</language>
<publisher>The Endocrine Society. The Journal&apos;s web site is located at http://jcem.endojournals.org</publisher>
<relation.ispartof>Journal of Clinical Endocrinology and Metabolism</relation.ispartof>
<subject.mesh>Adolescent</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Autoimmunity - Physiology</subject.mesh>
<subject.mesh>Blood Glucose - Analysis</subject.mesh>
<subject.mesh>Case-Control Studies</subject.mesh>
<subject.mesh>Child</subject.mesh>
<subject.mesh>Diabetes Mellitus - Blood - Classification</subject.mesh>
<subject.mesh>Diabetes Mellitus, Type 1 - Blood</subject.mesh>
<subject.mesh>Diabetes Mellitus, Type 2 - Blood</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Fibroblast Growth Factors - Analysis - Blood</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Insulin-Secreting Cells - Immunology</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<title>Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes</title>
<type>Article</type>
<description.nature>Link_to_OA_fulltext</description.nature>
<identifier.doi>10.1210/jc.2011-1930</identifier.doi>
<identifier.pmid>22013098</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84862928486</identifier.scopus>
<identifier.hkuros>204675</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84862928486&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>97</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>E54</identifier.spage>
<identifier.epage>E58</identifier.epage>
<publisher.place>United States</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/163504/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. Second Xiangya Hospital of Central-South University
  2. The University of Hong Kong